Description
Atorvastatin exhibits anti-hyperlipidemic, anti-inflammatory, anti-fibrotic, and cardioprotective activities. Atorvastatin acts as an inhibitor of HMG-CoA reductase, preventing cholesterol synthesis and decreasing levels of total cholesterol, triglycerides, and LDL and increasing levels of HDL. In animal models of renal ischemia/perfusion, atorvastatin decreases expression of toll-like receptor 4 (TLR4) an hmgb1, decreasing oxidative stress and inflammation. Additionally, atorvastatin inhibits left ventricular hypertrophy and cardiac fibrosis and decreases expression of HSP47 in animal models of heart failure.
References
Cai J, Yu X, Zhang B, et al. Atorvastatin improves survival of implanted stem cells in a rat model of renal ischemia-reperfusion injury. Am J Nephrol. 2014;39(6):466-75. PMID: 24854145.
Akahori H, Tsujino T, Naito Y, et al. Atorvastatin ameliorates cardiac fibrosis and improves left ventricular diastolic function in hypertensive diastolic heart failure model rats. J Hypertens. 2014 Jul;32(7):1534-41. PMID: 24759122.
Lea AP, McTavish D. Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs. 1997 May;53(5):828-47. PMID: 9129869.
Izumi S, Nozaki Y, Maeda K, et al. Investigation of the impact of substrate selection on in vitro organic anion transporting polypeptide 1B1 inhibition profiles for the prediction of drug-drug interactions. Drug Metab Dispos. 2015 Feb;43(2):235-247. PMID: 25414411.
